Is BPC-157 Legal in California? How to Access It Legally

Is any BPC-157 product FDA-approved?

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice, made as a free base or as an acetate salt that FDA treats as two different bulk substances [1]. No FDA-approved drug contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. Websites sell it as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only'; those are not FDA-approved drugs [1]. Compounded drugs in general are not FDA-approved either: FDA does not review their safety, effectiveness or quality before they reach patients [3].

Where BPC-157 sits in FDA's compounding rules

BPC-157 sat in FDA's category 2, bulk substances that may present significant safety risks when compounded, from September 2023 until April 22, 2026, when the nominating groups withdrew and it moved to a nominated-but-withdrawn table; removal was not a finding of safety [4]. It is in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), so the category 1 policy does not cover it, and it is not on the outsourcing-facility list (updated March 21, 2025) [5][6]. FDA's stated concerns remain: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', and FDA 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [4]. FDA's own reviewers proposed that BPC-157 not be added to the pharmacy bulks list [1]. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding it, against FDA staff's recommendation; news reports give the vote as 8 to 6 with 1 abstention [8][3]. The vote is advice only: BPC-157 is not on the list, and adding it needs formal rulemaking [8][3].

What the draft HHS policy says

HHS filed a notice on October 28, 2026 announcing a draft enforcement-discretion policy for six peptides including BPC-157, scheduled for Federal Register publication on October 30, 2026, with comments open for two weeks after [2][3]. For BPC-157 the draft requires the acetate form only, given subcutaneously, intramuscularly, orally or topically (nasal, rectal and intravenous are not listed), a single active ingredient, bulk substance from an FDA-registered manufacturer with a valid certificate of analysis meeting a peptide testing standard, a patient-specific prescription, and MedWatch reporting of serious adverse events and quality problems [3]. The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and it names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [2][3]. HHS may revisit it, for example if a safety signal or product quality issue appears [3].

What is known about safety

FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157, and its adverse-event search through December 4, 2025 found only 3 reports, all injectable; FDA said it cannot tell whether BPC-157 caused them [1]. A 2026 systematic review found 3 human studies with 30 patients in total, all of poor methodological quality, with certainty of evidence rated very low [9].